IGC Pharma's novel approach to
Alzheimer's Disease
Reach out to learn more about IGC-AD1's Phase 2b trial for agitation in dementia due to Alzheimer's
Latests Press Release
IGC Pharma’s Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
Alzheimer's disease affects over 55 million individuals worldwide 1
In treating agitation, which affects 40-80% of individuals with Alzheimer’s disease2, IGC-AD1 has shown promising results.
Drag to discover more
Impacting Lives: Our Work Matters
With no known cure for Alzheimer’s disease, our drugs have the potential to change lives.
5th Leading
Cause of death among
Americans aged 65+3
Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found3
From the CEO's desk:
Vertical integration
Periodic updates and perspectives on various aspects of our business.
Science Spotlight
Welcome to “Science Spotlight” – your exclusive platform for insights into neurological disorders. Dr. Juan Manuel Orjuela and the IGC Pharma scientific team bring you in-depth articles on conditions such as Alzheimer’s disease, offering comprehensive updates on treatment and understanding their impact on individuals and families. Explore the roles of caregivers and dynamics within affected families. Stay informed with our latest article.
- Feature Article
Key Insights into Pharmacokinetics: How Drugs “Know Where to Act” and Their Journey Through the Body
The journey of drugs within the body underscores pharmacokinetics as a cornerstone of effective drug development. By studying the ADME (Absorption, Distribution, Metabolism, and Excretion) phases, it highlights how each step influences the safety and efficacy of a drug. Understanding the dynamic interactions of drugs with the human body allows us to push the limits of medical science, ensuring that new therapies are not only potent, but also safe and fitted to meet the diverse needs of patients.
Investing in the Future: Building Brighter Lives for Children
At IGC Pharma, we recognize our commitment to patients, caregivers, and their families, including children. Explore our programs dedicated to children.
- World Health Organization, Dementia, Key facts, 15 March 2023.
- Van der Mussele S et al. Agitation-associated behavioral symptoms in MCI and Alzheimer’s dementia. Aging Ment Health 2014;19(3):247–57.
- Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5)
